Shandong Xinhua Pharmaceutical Company Limited reported consolidated and parent earnings results for the year ended December 31, 2017. For the year, on consolidated basis, the company reported gross revenue of RMB 4,515,716,784.19 compared to RMB 4,014,963,065.74 a year ago. Operating profit was RMB 281,680,867.72 compared to RMB 152,417,429.45 a year ago. Net profit was RMB 221,248,751.89 compared to RMB 133,047,273.87 a year ago. Net profit from continued operations was RMB 221,248,751.89 compared to RMB 133,047,273.87 a year ago. Net profit which belongs to shareholders of parent company was RMB 209,591,907.23 compared to RMB 122,271,549.68 a year ago. Basic and diluted earnings per share was RMB 0.45 compared to RMB 0.27 a year ago. Net cash flow from operating activities was RMB 389,971,809.35 compared to RMB 439,348,332.79 a year ago. Cash paid for purchasing and constructing fixed assets, intangible assets and other long-term assets was RMB 261,108,044.61 compared to RMB 227,068,193.90 a year ago. Return on net assets was 9.70% compared to 6.31% a year ago. For the year, on parent basis, the company reported Operating revenue of RMB 2,349,073,811.37 compared to RMB 2,097,279,861.24 a year ago. Operating profit was RMB 175,629,655.46 compared to RMB 67,011,834.40 a year ago. Net profit was RMB 142,916,897.12 compared to RMB 77,523,616.79 a year ago. Net profit from continued operations was RMB 142,916,897.12 compared to RMB 77,523,616.79 a year ago. Net cash flow from operating activities was RMB 292,525,492.44 compared to RMB 326,230,339.80 a year ago. Cash paid for purchasing and constructing fixed assets, intangible assets and other long-term assets was RMB 206,708,281.99 compared to RMB 183,725,083.41 a year ago.